Form 8-K - Current report:
SEC Accession No. 0001641172-25-013417
Filing Date
2025-06-03
Accepted
2025-06-03 15:00:44
Documents
15
Period of Report
2025-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 43858
2 EX-1.1 ex1-1.htm EX-1.1 255205
3 EX-5.1 ex5-1.htm EX-5.1 11637
  Complete submission text file 0001641172-25-013417.txt   538134

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE immx-20250603.xsd EX-101.SCH 3014
5 XBRL LABEL FILE immx-20250603_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE immx-20250603_pre.xml EX-101.PRE 22358
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3814
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

EIN.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41159 | Film No.: 251018862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)